AU2022399413A1 - Methods and compositions for maintaining and expanding hematopoietic stem cells - Google Patents
Methods and compositions for maintaining and expanding hematopoietic stem cells Download PDFInfo
- Publication number
- AU2022399413A1 AU2022399413A1 AU2022399413A AU2022399413A AU2022399413A1 AU 2022399413 A1 AU2022399413 A1 AU 2022399413A1 AU 2022399413 A AU2022399413 A AU 2022399413A AU 2022399413 A AU2022399413 A AU 2022399413A AU 2022399413 A1 AU2022399413 A1 AU 2022399413A1
- Authority
- AU
- Australia
- Prior art keywords
- agonist
- hscs
- culture media
- concentration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title description 10
- 239000001963 growth medium Substances 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims abstract description 52
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims abstract description 38
- 239000000556 agonist Substances 0.000 claims description 133
- 102000036693 Thrombopoietin Human genes 0.000 claims description 63
- 108010041111 Thrombopoietin Proteins 0.000 claims description 63
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 55
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 55
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical group [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 53
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 51
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 51
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 49
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 48
- 229960000604 valproic acid Drugs 0.000 claims description 48
- 230000037361 pathway Effects 0.000 claims description 40
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 39
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 39
- -1 ebeselen Chemical compound 0.000 claims description 38
- 239000003112 inhibitor Substances 0.000 claims description 37
- ZUDXFBWDXVNRKF-UHFFFAOYSA-N 5,11-dihydroindolo[3,2-b]carbazole-12-carboxaldehyde Chemical group N1C2=CC=CC=C2C2=C1C=C1C3=CC=CC=C3NC1=C2C=O ZUDXFBWDXVNRKF-UHFFFAOYSA-N 0.000 claims description 34
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 33
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 33
- 230000000975 bioactive effect Effects 0.000 claims description 33
- 150000003904 phospholipids Chemical class 0.000 claims description 33
- 102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 claims description 30
- 101000921095 Homo sapiens Corticotropin-releasing factor-binding protein Proteins 0.000 claims description 30
- 108010023082 activin A Proteins 0.000 claims description 30
- PDGVGAAXMRKVPG-UHFFFAOYSA-N C(C)(C)C1=CC=C(C=C1)NC1=NC2=CC=CC(=C2C(=N1)N)OC1=CC(=CC=C1)OC Chemical group C(C)(C)C1=CC=C(C=C1)NC1=NC2=CC=CC(=C2C(=N1)N)OC1=CC(=CC=C1)OC PDGVGAAXMRKVPG-UHFFFAOYSA-N 0.000 claims description 27
- 102100034196 Thrombopoietin receptor Human genes 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 235000019154 vitamin C Nutrition 0.000 claims description 25
- 239000011718 vitamin C Substances 0.000 claims description 25
- 239000003963 antioxidant agent Substances 0.000 claims description 23
- 235000006708 antioxidants Nutrition 0.000 claims description 23
- 230000003078 antioxidant effect Effects 0.000 claims description 21
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 19
- 102000003964 Histone deacetylase Human genes 0.000 claims description 19
- 108090000353 Histone deacetylase Proteins 0.000 claims description 19
- 229930003268 Vitamin C Natural products 0.000 claims description 19
- 102100020880 Kit ligand Human genes 0.000 claims description 15
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 15
- 210000004700 fetal blood Anatomy 0.000 claims description 14
- 230000007774 longterm Effects 0.000 claims description 12
- HORZNQYQXBFWNZ-LBPRGKRZSA-N (6as)-2,10-dimethoxy-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1,9-diol Chemical group N1CCC2=CC(OC)=C(O)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 HORZNQYQXBFWNZ-LBPRGKRZSA-N 0.000 claims description 10
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 10
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 10
- ZQQLMECVOXKFJK-NXCSZAMKSA-N N-octadecanoylsphingosine 1-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP(O)(O)=O)[C@H](O)\C=C\CCCCCCCCCCCCC ZQQLMECVOXKFJK-NXCSZAMKSA-N 0.000 claims description 10
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical group C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 10
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 10
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 claims description 10
- 102100028798 Homeodomain-only protein Human genes 0.000 claims description 8
- 101000839095 Homo sapiens Homeodomain-only protein Proteins 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- VQQGPFFHGWNIGX-PPCHTBMASA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-[(2s,3r,4s,5s)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a, Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H](OC[C@H](O)[C@@H]2O)O[C@@H]2C([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)C)O[C@H](CO)[C@@H](O)[C@@H]1O VQQGPFFHGWNIGX-PPCHTBMASA-N 0.000 claims description 5
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 claims description 5
- BLVQHYHDYFTPDV-VCABWLAWSA-N (e)-n-(2-amino-4-fluorophenyl)-3-[1-[(e)-3-phenylprop-2-enyl]pyrazol-4-yl]prop-2-enamide Chemical compound NC1=CC(F)=CC=C1NC(=O)\C=C\C1=CN(C\C=C\C=2C=CC=CC=2)N=C1 BLVQHYHDYFTPDV-VCABWLAWSA-N 0.000 claims description 5
- PRXXYMVLYKJITB-IZZDOVSWSA-N (e)-n-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide Chemical compound C1=NN(C)C=C1C1=CC=C(S(=O)(=O)N2C=C(\C=C\C(=O)NC=3C(=CC=CC=3)N)C=C2)C=C1 PRXXYMVLYKJITB-IZZDOVSWSA-N 0.000 claims description 5
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 5
- UVNLAUGZMOPBPR-UHFFFAOYSA-N 1-(2,4-dichlorobenzoyl)-1H-1,2,3-benzotriazole Chemical compound ClC1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2N=N1 UVNLAUGZMOPBPR-UHFFFAOYSA-N 0.000 claims description 5
- OFZJKCQENFPZBH-UHFFFAOYSA-N 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C1=NC=C(C(=O)NC=2SC(=C(C=3SC=C(Cl)C=3)N=2)N2CCN(CC2)C2CCCCC2)C=C1Cl OFZJKCQENFPZBH-UHFFFAOYSA-N 0.000 claims description 5
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 claims description 5
- KDDXOGDIPZSCTM-UHFFFAOYSA-N 2-[1H-indol-3-yl(oxo)methyl]-4-thiazolecarboxylic acid methyl ester Chemical compound COC(=O)C1=CSC(C(=O)C=2C3=CC=CC=C3NC=2)=N1 KDDXOGDIPZSCTM-UHFFFAOYSA-N 0.000 claims description 5
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 5
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 claims description 5
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 5
- JZWXMCPARMXZQV-UHFFFAOYSA-N 4-[[butyl(phenylcarbamoyl)amino]methyl]-n-hydroxybenzamide Chemical compound C=1C=CC=CC=1NC(=O)N(CCCC)CC1=CC=C(C(=O)NO)C=C1 JZWXMCPARMXZQV-UHFFFAOYSA-N 0.000 claims description 5
- BVQCFCYPFJOOAV-UHFFFAOYSA-N 4-bromo-n'-butylbenzohydrazide Chemical compound CCCCNNC(=O)C1=CC=C(Br)C=C1 BVQCFCYPFJOOAV-UHFFFAOYSA-N 0.000 claims description 5
- ALBQXDHCMLLQMB-UHFFFAOYSA-N 4-phenylbenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 ALBQXDHCMLLQMB-UHFFFAOYSA-N 0.000 claims description 5
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 5
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 claims description 5
- GISXTRIGVCKQBX-UHFFFAOYSA-N 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-n-hydroxyheptanamide Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCCCCC(=O)NO)=NC2=C1 GISXTRIGVCKQBX-UHFFFAOYSA-N 0.000 claims description 5
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 5
- QQDIFLSJMFDTCQ-UHFFFAOYSA-N MC1568 Chemical compound CN1C(C=CC(=O)NO)=CC=C1C=CC(=O)C1=CC=CC(F)=C1 QQDIFLSJMFDTCQ-UHFFFAOYSA-N 0.000 claims description 5
- LMWPVSNHKACEKW-UHFFFAOYSA-N N-(2-aminophenyl)-2-pyrazinecarboxamide Chemical compound NC1=CC=CC=C1NC(=O)C1=CN=CC=N1 LMWPVSNHKACEKW-UHFFFAOYSA-N 0.000 claims description 5
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 5
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims description 5
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims description 5
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 5
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 claims description 5
- AJRGHIGYPXNABY-UHFFFAOYSA-N N-hydroxy-1-[(4-methoxyphenyl)methyl]-6-indolecarboxamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC(C(=O)NO)=CC=C2C=C1 AJRGHIGYPXNABY-UHFFFAOYSA-N 0.000 claims description 5
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 claims description 5
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 claims description 5
- VQQGPFFHGWNIGX-UHFFFAOYSA-N Raddeanin A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O VQQGPFFHGWNIGX-UHFFFAOYSA-N 0.000 claims description 5
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 5
- 229950008805 abexinostat Drugs 0.000 claims description 5
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 229950011007 avatrombopag Drugs 0.000 claims description 5
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 5
- 229960003094 belinostat Drugs 0.000 claims description 5
- PIDGGJYETVQYET-UHFFFAOYSA-N chembl173171 Chemical compound C12=CC=C(Br)C=C2N(C)C(O)=C1C1=C(N=O)C2=CC=CC=C2N1 PIDGGJYETVQYET-UHFFFAOYSA-N 0.000 claims description 5
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 claims description 5
- 229940069588 citarinostat Drugs 0.000 claims description 5
- 235000012754 curcumin Nutrition 0.000 claims description 5
- 239000004148 curcumin Substances 0.000 claims description 5
- 229940109262 curcumin Drugs 0.000 claims description 5
- AFDPFLDWOXXHQM-NRFANRHFSA-N cyclopentyl (2s)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate Chemical compound C1=NC(CCC(=O)NO)=CC=C1CN[C@H](C(=O)OC1CCCC1)C1CCCCC1 AFDPFLDWOXXHQM-NRFANRHFSA-N 0.000 claims description 5
- 229950005259 dacinostat Drugs 0.000 claims description 5
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 5
- 229940028937 divalproex sodium Drugs 0.000 claims description 5
- HORZNQYQXBFWNZ-UHFFFAOYSA-N dl-Norisoboldin Natural products N1CCC2=CC(OC)=C(O)C3=C2C1CC1=C3C=C(OC)C(O)=C1 HORZNQYQXBFWNZ-UHFFFAOYSA-N 0.000 claims description 5
- 229940088079 domatinostat Drugs 0.000 claims description 5
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical group CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 claims description 5
- 229960001069 eltrombopag Drugs 0.000 claims description 5
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 5
- 229950005837 entinostat Drugs 0.000 claims description 5
- 229940121280 fimepinostat Drugs 0.000 claims description 5
- 229950010415 givinostat Drugs 0.000 claims description 5
- 229960003180 glutathione Drugs 0.000 claims description 5
- NOZIJMHMKORZBA-KJCUYJGMSA-N lusutrombopag Chemical compound CCCCCCO[C@@H](C)C1=CC=CC(C=2N=C(NC(=O)C=3C=C(Cl)C(\C=C(/C)C(O)=O)=C(Cl)C=3)SC=2)=C1OC NOZIJMHMKORZBA-KJCUYJGMSA-N 0.000 claims description 5
- 229950009491 lusutrombopag Drugs 0.000 claims description 5
- 229950007812 mocetinostat Drugs 0.000 claims description 5
- QTCSXAUJBQZZSN-UHFFFAOYSA-N n-[2-methyl-2-(2-phenyl-1,3-oxazol-4-yl)propyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Chemical compound C=1OC(C=2C=CC=CC=2)=NC=1C(C)(C)CNC(=O)C(C=1)=CC=CC=1C1=NOC(C(F)(F)F)=N1 QTCSXAUJBQZZSN-UHFFFAOYSA-N 0.000 claims description 5
- VOPDXHFYDJAYNS-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCCCCCC(=O)NC1=CC=CC=C1N VOPDXHFYDJAYNS-UHFFFAOYSA-N 0.000 claims description 5
- HORXBWNTEDOVKN-UHFFFAOYSA-N n-[[4-(4-phenyl-1,3-thiazol-2-yl)oxan-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Chemical compound O1C(C(F)(F)F)=NC(C=2C=C(C=CC=2)C(=O)NCC2(CCOCC2)C=2SC=C(N=2)C=2C=CC=CC=2)=N1 HORXBWNTEDOVKN-UHFFFAOYSA-N 0.000 claims description 5
- LIIWIMDSZVNYHY-UHFFFAOYSA-N n-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=CC=CC=2)CC1 LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 claims description 5
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 claims description 5
- RFAZNTABYJYOAR-UHFFFAOYSA-N n-hydroxy-4-[2-[n-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide Chemical compound C=1C=CC=CC=1N(CCO)C(=O)CC1=CC=C(C(=O)NO)C=C1 RFAZNTABYJYOAR-UHFFFAOYSA-N 0.000 claims description 5
- 229960005184 panobinostat Drugs 0.000 claims description 5
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 5
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 claims description 5
- 229940069510 parthenolide Drugs 0.000 claims description 5
- 229950009215 phenylbutanoic acid Drugs 0.000 claims description 5
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 claims description 5
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 claims description 5
- 229950003618 pracinostat Drugs 0.000 claims description 5
- 229950010654 quisinostat Drugs 0.000 claims description 5
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 claims description 5
- 229950002821 resminostat Drugs 0.000 claims description 5
- 229950006743 ricolinostat Drugs 0.000 claims description 5
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 5
- 229960003452 romidepsin Drugs 0.000 claims description 5
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 5
- 108010091666 romidepsin Proteins 0.000 claims description 5
- HTOYBIILVCHURC-UHFFFAOYSA-N santacruzamate A Chemical compound CCOC(=O)NCCCC(=O)NCCC1=CC=CC=C1 HTOYBIILVCHURC-UHFFFAOYSA-N 0.000 claims description 5
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 claims description 5
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 claims description 5
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 5
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims description 5
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims description 5
- ISFPDBUKMJDAJH-UHFFFAOYSA-N splitomicin Chemical compound C1=CC2=CC=CC=C2C2=C1OC(=O)CC2 ISFPDBUKMJDAJH-UHFFFAOYSA-N 0.000 claims description 5
- 229960005559 sulforaphane Drugs 0.000 claims description 5
- 235000015487 sulforaphane Nutrition 0.000 claims description 5
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 5
- 229950011110 tacedinaline Drugs 0.000 claims description 5
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 claims description 5
- 229950001899 tasquinimod Drugs 0.000 claims description 5
- 229940070131 tinostamustine Drugs 0.000 claims description 5
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 5
- 229950001415 tucidinostat Drugs 0.000 claims description 5
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 5
- 229960000237 vorinostat Drugs 0.000 claims description 5
- IYBURCQQEUNLDL-UHFFFAOYSA-N 2-[[1-(3-fluorophenyl)cyclohexyl]amino]-n-hydroxypyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=C(F)C=CC=2)CCCCC1 IYBURCQQEUNLDL-UHFFFAOYSA-N 0.000 claims description 4
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940087168 alpha tocopherol Drugs 0.000 claims description 4
- VRYZCEONIWEUAV-UHFFFAOYSA-N n-[6-(hydroxyamino)-6-oxohexoxy]-3,5-dimethylbenzamide Chemical compound CC1=CC(C)=CC(C(=O)NOCCCCCC(=O)NO)=C1 VRYZCEONIWEUAV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims description 3
- 102100023876 Rhombotin-2 Human genes 0.000 claims description 3
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims 7
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 35
- 239000012636 effector Substances 0.000 description 30
- 102100031785 Endothelial transcription factor GATA-2 Human genes 0.000 description 25
- 101001066265 Homo sapiens Endothelial transcription factor GATA-2 Proteins 0.000 description 25
- 102000005650 Notch Receptors Human genes 0.000 description 20
- 108010070047 Notch Receptors Proteins 0.000 description 20
- 101100022813 Zea mays MEG3 gene Proteins 0.000 description 20
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 102100023075 Protein Niban 2 Human genes 0.000 description 18
- 238000012423 maintenance Methods 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 10
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 10
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 9
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102100025110 Homeobox protein Hox-A5 Human genes 0.000 description 6
- 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000001759 Notch1 Receptor Human genes 0.000 description 5
- 108010029755 Notch1 Receptor Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000018706 hematopoietic system disease Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 3
- 102100033167 Elastin Human genes 0.000 description 3
- 102100039121 Histone-lysine N-methyltransferase MECOM Human genes 0.000 description 3
- 101100076418 Homo sapiens MECOM gene Proteins 0.000 description 3
- 101000959489 Homo sapiens Protein AF-9 Proteins 0.000 description 3
- 108700024831 MDS1 and EVI1 Complex Locus Proteins 0.000 description 3
- 108700035965 MEG3 Proteins 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 102100039686 Protein AF-9 Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 description 2
- 101100076419 Mus musculus Mecom gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013400 design of experiment Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- SAYGKHKXGCPTLX-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-fluorophenyl)-3-thiophenecarboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(F)=CC=2)=C1 SAYGKHKXGCPTLX-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000027755 Blood autoimmune disease Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001046587 Homo sapiens Krueppel-like factor 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
- 101001077727 Homo sapiens Serine protease inhibitor Kazal-type 2 Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100022248 Krueppel-like factor 1 Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 102100025419 Serine protease inhibitor Kazal-type 2 Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000017047 asymmetric cell division Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- YSYMCIKNYHKBHZ-UHFFFAOYSA-N cytosporin B Natural products O1C(C)(C)C(O)CC2(O)C(Cl)C(O)C(CCCCC)=C(C=O)C21 YSYMCIKNYHKBHZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 description 1
- GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HWJRIFZDXJKJJN-UHFFFAOYSA-N n-(1h-pyrrolo[2,3-c]pyridin-5-yl)benzamide Chemical compound C=1C=2C=CNC=2C=NC=1NC(=O)C1=CC=CC=C1 HWJRIFZDXJKJJN-UHFFFAOYSA-N 0.000 description 1
- QRJTZIJWDLJKQO-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(6-hydroxy-3,4-dihydro-2h-quinolin-1-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CCC2=CC(O)=CC=C2N1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)NCC1CC1 QRJTZIJWDLJKQO-UHFFFAOYSA-N 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 101150038319 oac1 gene Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- BQNXBSYSQXSXPT-UHFFFAOYSA-N yoda 1 Chemical compound ClC1=CC=CC(Cl)=C1CSC1=NN=C(C=2N=CC=NC=2)S1 BQNXBSYSQXSXPT-UHFFFAOYSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284360P | 2021-11-30 | 2021-11-30 | |
| US63/284,360 | 2021-11-30 | ||
| PCT/US2022/051195 WO2023101943A1 (en) | 2021-11-30 | 2022-11-29 | Methods and compositions for maintaining and expanding hematopoietic stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022399413A1 true AU2022399413A1 (en) | 2024-05-23 |
Family
ID=84901401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022399413A Pending AU2022399413A1 (en) | 2021-11-30 | 2022-11-29 | Methods and compositions for maintaining and expanding hematopoietic stem cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230167408A1 (https=) |
| EP (1) | EP4441205A1 (https=) |
| JP (1) | JP2024541616A (https=) |
| KR (1) | KR20240110653A (https=) |
| CN (1) | CN118302519A (https=) |
| AU (1) | AU2022399413A1 (https=) |
| CA (1) | CA3238518A1 (https=) |
| IL (1) | IL312661A (https=) |
| WO (1) | WO2023101943A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080674A1 (en) | 2023-10-09 | 2025-04-17 | Trailhead Biosystems Inc. | Methods to improve enduring hematopoietic stem cell transplantation |
| WO2025129033A1 (en) * | 2023-12-14 | 2025-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for hematopoietic stem and progenitor cell expansion |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2488425A1 (en) * | 2002-06-07 | 2003-12-18 | Es Cell International Pte Ltd | Methods of regulating differentiation in stem cells |
| CA2948871A1 (en) * | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| US10669528B2 (en) * | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| EP4049665B1 (en) * | 2016-03-15 | 2025-03-12 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US20180163177A1 (en) * | 2016-12-11 | 2018-06-14 | Healthbanks Biotech Co. Ltd. | Serum-free culture medium and method for expanding hematopoietic stem cells |
| GB201706544D0 (en) * | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
| CN114286860A (zh) * | 2019-08-29 | 2022-04-05 | 味之素株式会社 | 由含有间充质干细胞的生物来源细胞试样制造间充质干细胞的方法 |
-
2022
- 2022-11-29 WO PCT/US2022/051195 patent/WO2023101943A1/en not_active Ceased
- 2022-11-29 EP EP22840471.1A patent/EP4441205A1/en active Pending
- 2022-11-29 KR KR1020247021309A patent/KR20240110653A/ko active Pending
- 2022-11-29 IL IL312661A patent/IL312661A/en unknown
- 2022-11-29 AU AU2022399413A patent/AU2022399413A1/en active Pending
- 2022-11-29 CA CA3238518A patent/CA3238518A1/en active Pending
- 2022-11-29 JP JP2024532440A patent/JP2024541616A/ja active Pending
- 2022-11-29 CN CN202280078418.7A patent/CN118302519A/zh active Pending
- 2022-11-29 US US18/071,388 patent/US20230167408A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL312661A (en) | 2024-07-01 |
| CN118302519A (zh) | 2024-07-05 |
| JP2024541616A (ja) | 2024-11-08 |
| WO2023101943A1 (en) | 2023-06-08 |
| KR20240110653A (ko) | 2024-07-15 |
| EP4441205A1 (en) | 2024-10-09 |
| US20230167408A1 (en) | 2023-06-01 |
| CA3238518A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lauridsen et al. | Differences in cell cycle status underlie transcriptional heterogeneity in the HSC compartment | |
| US20230167408A1 (en) | Methods and compositions for maintaining and expanding hematopoietic stem cells | |
| US20130136722A1 (en) | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts | |
| CN110268048B (zh) | 从人多能干细胞生成心房心肌细胞和心室心肌细胞谱系 | |
| Gao et al. | Tetrahydroxy stilbene glucoside rejuvenates aging hematopoietic stem cells with predilection for lymphoid differentiation via AMPK and Tet2 | |
| Chen et al. | miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape | |
| Zippel et al. | A parallelized, perfused 3D triculture model of leukemia for in vitro drug testing of chemotherapeutics | |
| Cui et al. | Synergistic effect and molecular mechanism of nicotinamide and UM171 in ex vivo expansion of long-term hematopoietic stem cells | |
| JP2024542842A (ja) | ヒト赤血球系前駆細胞を作製するための方法および組成物 | |
| Migliaccio et al. | Under HEMA conditions, self-replication of human erythroblasts is limited by autophagic death | |
| Tatetsu et al. | Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465) | |
| EP3452581B1 (en) | 4hpr and its use in the culturing of hematopoietic stem cells | |
| Uslu et al. | Development of a novel and synthetic HematoMiR technology that broadly modulates quiescence of stem cells and enhances HSC expansion | |
| Poscablo | Alterations to Platelet Differentiation Pathways Arising From Hematopoietic Stem Cells During Aging | |
| US20250115871A1 (en) | Methods to improve enduring hematopoietic stem cell transplantation | |
| Huang | ZFP36L2 in Development and Adulthood: A Critical Regulator of Hematopoietic Stem Cell Homeostasis | |
| Bozok et al. | A new transciription factor in hematopoiesis | |
| Chen | Regulation of human hematopoietic stem cell lineage commitment | |
| Pirsavabi et al. | Ex vivo culture of hematopoietic stem and progenitor cells with platelet lysate: Investigating proliferation and erythroid-megakaryocytic lineage effects | |
| Malik et al. | mTORC1 activity is essential for disease progression in chronic lymphocytic leukemia | |
| Keyvani Chahi | CHARACTERIZING THE ROLE OF THE TRANSCRIPTION FACTOR PLAG1 IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS | |
| Sousae | Methylation of histone H3 lysine-9 regulates hematopoietic stem cell differentiation | |
| Rosenlehner | Reciprocal regulation of mTORC1 and ribosomal biosynthesis determines cell cycle progression in activated T cells | |
| Feng | Using human pluripotent stem cells to discover differentiation inducers for the treatment of acute myeloid leukemia | |
| Grušanović | Identification and characterization of novel regulators of hematopoietic stem cell function |